Global Drug Eluting Stents (DES) Market By Type (Sirolimus Stents, Paclitaxel Stents, Everolimus Stents, Zotarolimus Stents, Biolimus Stents) By Platform Material (Cobalt Chromium, Platinum Chromium, Stainless steel, Others) By Polymer Type (Durable, Biodegradable, Polymer Free) By End Users (Hospitals, Ambulatory Surgical Centers, Cardiology centers, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
In terms of revenue, the global drug eluting stents (DES) market was worth US$ 2.8 Bn in 2022, expected to gain CAGR of 6.6% over the forecast period (2023 – 2031).
Drug eluting stents (DES) are used to treat narrow or clogged arteries, which can lead to conditions such as angina (chest pain) or a heart attack. These types of stents release medication over time to prevent new blockages from forming after the stent is implanted. The demand for drug eluting stents (DES) market is driven by several factors, including:
- Increasing prevalence of cardiovascular diseases: The prevalence of cardiovascular diseases is on the rise globally, which is increasing the demand for treatment options such as DES.
- Technological advancements in stent designs: Advances in stent design have led to the development of newer, more effective DES that offer improved outcomes compared to earlier generations of stents.
- Rising demand for minimally invasive procedures: Minimally invasive procedures are becoming increasingly popular among patients due to their lower risk of complications, shorter recovery times, and reduced hospital stays, which is driving demand for drug eluting stents (DES) market.
- Growing aging population: The global aging population is increasing, and older adults are more susceptible to conditions such as coronary artery disease, which is driving demand for treatment options such as DES.
- Rising healthcare expenditure: As healthcare expenditure increases globally, there is more investment in the development and adoption of new, innovative treatments such as drug-eluting stents.
The combination of these factors is expected to drive significant demand for drug eluting stents (DES) market in the coming years. In addition, the ongoing research and development in this field are likely to lead to further improvements in DES technology, which will further boost demand.
Global Drug Eluting Stents (DES) Market Revenue & Forecast, (US$ Million), 2015 – 2031
As of 2022, durable polymer-based drug-eluting stents accounted for the largest market share, followed by biodegradable polymer-based drug-eluting stents. This can be attributed to the fact that durable polymer-based stents have been used for a long time and have a proven safety and efficacy record. Furthermore, these stents use a polymer coating that remains in place for an extended period of time, typically several months to a few years, in order to control the drug release rate. For instance, The Promus stent by Boston Scientific Corporation is also a DP-DES that uses a cobalt-chromium alloy stent platform and a polytetrafluoroethylene-coated polymer. It delivers everolimus to prevent restenosis.
Biodegradable polymer-based stents are becoming increasingly popular, it is expected that they will gain higher market share in the future in the global drug eluting stents (DES) market due to their inherent advantages of reduced long-term inflammation and thrombosis risk. Polymer-free drug-eluting stents on the other hand are a relatively new development, and they currently occupy a small share of the market. They are gaining traction due to their ability to provide drug delivery without a polymer, thereby reducing the complications associated with polymer inflammation and thrombosis.
Regional Outlook
In the United States, the use of DES is widespread, with over one million stent procedures performed each year. DES are covered by most insurance plans, and many hospitals have adopted them as the default treatment for patients with coronary artery disease. The most commonly used DES in the U.S. are made by Abbott, Boston Scientific, and Medtronic. In Canada, the use of DES is also widespread, with an estimated 60,000 stent procedures performed each year. The most commonly used DES in Canada are made by Abbott, Boston Scientific, and Terumo. According to a recent survey by the American College of Cardiology, more than 75% of respondents reported using at least one type of DES in their practice. Drug eluting stents (DES) market in North America has continued to grow over the last decade, with new technologies such as biodegradable polymer and polymer-free stents contributing to that growth. The most commonly implanted type of DES is still the durable polymer drug-eluting stent, which accounted for nearly 75% of all DES implanted in 2022.
Competitive Landscape
The report provides both, qualitative and quantitative research of global drug eluting stents (DES) market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Global Drug Eluting Stents (DES) Market Competitors
- Abbott
- Alvimedica
- BIOTRONIK SE & Co KG
- Boston Scientific Corporation
- Cardionovum GmbH
- Cook Medical
- Lepu Medical
- Medtronic
- Micropart Medical (Group) Co.,Ltd
- Terumo Corporation (Essen Technology Co., Ltd)
- Other Market Participants
Global Drug Eluting Stents(DES) Market:
By Type
- Sirolimus stents
- Paclitaxel stents
- Everolimus stents
- Zotarolimus stents
Biolimus stents
By Platform Material
- Cobalt Chromium
- Platinum Chromium
- Stainless steel
- Others
By Polymer Type
- Durable
- Biodegradable
- Polymer Free
By End Users
- Hospitals
- Ambulatory Surgical Centers
- Cardiology centers
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2022
1.2.3. Forecast
Years: 2023 - 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Drug Eluting Stents(DES) Market
6. Market Synopsis: Drug
Eluting Stents(DES) Market
7. Drug Eluting Stents(DES) Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Drug Eluting Stents(DES) Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Drug Eluting Stents(DES) Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Drug Eluting Stents(DES) Market
8. Global Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
8.1. Overview
8.1.1. Global
Drug Eluting Stents(DES) Market Revenue (US$ Mn)
8.2. Global
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Sirolimus
stents
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2022
8.2.1.3. Market Forecast, 2023 - 2031
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2022
8.2.1.5.1.2. Market
Forecast, 2023 - 2031
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2022
8.2.1.5.2.2. Market
Forecast, 2023 - 2031
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2022
8.2.1.5.3.2. Market
Forecast, 2023 - 2031
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2022
8.2.1.5.4.2. Market
Forecast, 2023 - 2031
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2022
8.2.1.5.5.2. Market
Forecast, 2023 - 2031
8.2.2. Paclitaxel
stents
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2022
8.2.2.3. Market Forecast, 2023 - 2031
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2022
8.2.2.5.1.2. Market
Forecast, 2023 - 2031
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2022
8.2.2.5.2.2. Market
Forecast, 2023 - 2031
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2022
8.2.2.5.3.2. Market
Forecast, 2023 - 2031
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2022
8.2.2.5.4.2. Market
Forecast, 2023 - 2031
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2022
8.2.2.5.5.2. Market
Forecast, 2023 - 2031
8.2.3. Everolimus stents
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2022
8.2.3.3. Market Forecast, 2023 - 2031
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2022
8.2.3.5.1.2. Market
Forecast, 2023 - 2031
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2022
8.2.3.5.2.2. Market
Forecast, 2023 - 2031
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2022
8.2.3.5.3.2. Market
Forecast, 2023 - 2031
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2022
8.2.3.5.4.2. Market
Forecast, 2023 - 2031
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2022
8.2.3.5.5.2. Market
Forecast, 2023 - 2031
8.2.4. Zotarolimus
stents
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2022
8.2.4.3. Market Forecast, 2023 - 2031
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2022
8.2.4.5.1.2. Market
Forecast, 2023 - 2031
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2022
8.2.4.5.2.2. Market
Forecast, 2023 - 2031
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2022
8.2.4.5.3.2. Market
Forecast, 2023 - 2031
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2022
8.2.4.5.4.2. Market
Forecast, 2023 - 2031
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2022
8.2.4.5.5.2. Market
Forecast, 2023 - 2031
8.2.5. Biolimus
stents
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2022
8.2.5.3. Market Forecast, 2023 - 2031
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2022
8.2.5.5.1.2. Market
Forecast, 2023 - 2031
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2022
8.2.5.5.2.2. Market
Forecast, 2023 - 2031
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2022
8.2.5.5.3.2. Market
Forecast, 2023 - 2031
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2022
8.2.5.5.4.2. Market
Forecast, 2023 - 2031
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2022
8.2.5.5.5.2. Market
Forecast, 2023 - 2031
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
9.1. Overview
9.2. Global
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Material
9.2.1. Cobalt
Chromium
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2022
9.2.1.3. Market Forecast, 2023 - 2031
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2022
9.2.1.5.1.2. Market
Forecast, 2023 - 2031
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2022
9.2.1.5.2.2. Market
Forecast, 2023 - 2031
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2022
9.2.1.5.3.2. Market
Forecast, 2023 - 2031
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2022
9.2.1.5.4.2. Market
Forecast, 2023 - 2031
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2022
9.2.1.5.5.2. Market
Forecast, 2023 - 2031
9.2.2. Platinum
Chromium
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2022
9.2.2.3. Market Forecast, 2023 - 2031
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2022
9.2.2.5.1.2. Market
Forecast, 2023 - 2031
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2022
9.2.2.5.2.2. Market
Forecast, 2023 - 2031
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2022
9.2.2.5.3.2. Market
Forecast, 2023 - 2031
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2022
9.2.2.5.4.2. Market
Forecast, 2023 - 2031
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2022
9.2.2.5.5.2. Market
Forecast, 2023 - 2031
9.2.3. Stainless
steel
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2022
9.2.3.3. Market Forecast, 2023 - 2031
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2022
9.2.3.5.1.2. Market
Forecast, 2023 - 2031
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2022
9.2.3.5.2.2. Market
Forecast, 2023 - 2031
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2022
9.2.3.5.3.2. Market
Forecast, 2023 - 2031
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2022
9.2.3.5.4.2. Market
Forecast, 2023 - 2031
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2022
9.2.3.5.5.2. Market
Forecast, 2023 - 2031
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2022
9.2.4.3. Market Forecast, 2023 - 2031
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2022
9.2.4.5.1.2. Market
Forecast, 2023 - 2031
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2022
9.2.4.5.2.2. Market
Forecast, 2023 - 2031
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2022
9.2.4.5.3.2. Market
Forecast, 2023 - 2031
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2022
9.2.4.5.4.2. Market
Forecast, 2023 - 2031
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2022
9.2.4.5.5.2. Market
Forecast, 2023 - 2031
9.3. Key
Segment for Channeling Investments
9.3.1. By
Material
10. Global Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
10.1. Overview
10.2. Global Drug
Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Polymer Type
10.2.1. Durable
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2022
10.2.1.3. Market Forecast, 2023 - 2031
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2022
10.2.1.5.1.2. Market
Forecast, 2023 - 2031
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2022
10.2.1.5.2.2. Market
Forecast, 2023 - 2031
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2022
10.2.1.5.3.2. Market
Forecast, 2023 - 2031
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2022
10.2.1.5.4.2. Market
Forecast, 2023 - 2031
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2022
10.2.1.5.5.2. Market
Forecast, 2023 - 2031
10.2.2. Biodegradable
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2022
10.2.2.3. Market Forecast, 2023 - 2031
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2022
10.2.2.5.1.2. Market
Forecast, 2023 - 2031
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2022
10.2.2.5.2.2. Market
Forecast, 2023 - 2031
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2022
10.2.2.5.3.2. Market
Forecast, 2023 - 2031
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2022
10.2.2.5.4.2. Market
Forecast, 2023 - 2031
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2022
10.2.2.5.5.2. Market
Forecast, 2023 - 2031
10.2.3. Polymer
Free
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2022
10.2.3.3. Market Forecast, 2023 - 2031
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2022
10.2.3.5.1.2. Market
Forecast, 2023 - 2031
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2022
10.2.3.5.2.2. Market
Forecast, 2023 - 2031
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2022
10.2.3.5.3.2. Market
Forecast, 2023 - 2031
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2022
10.2.3.5.4.2. Market
Forecast, 2023 - 2031
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2022
10.2.3.5.5.2. Market
Forecast, 2023 - 2031
10.3. Key
Segment for Channeling Investments
10.3.1. By
Polymer Type
11. Global Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
11.1. Overview
11.2. Global
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2022
11.2.1.3. Market Forecast, 2023 - 2031
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2022
11.2.1.5.1.2. Market
Forecast, 2023 - 2031
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2022
11.2.1.5.2.2. Market
Forecast, 2023 - 2031
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2022
11.2.1.5.3.2. Market
Forecast, 2023 - 2031
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2022
11.2.1.5.4.2. Market
Forecast, 2023 - 2031
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2022
11.2.1.5.5.2. Market
Forecast, 2023 - 2031
11.2.2. Ambulatory
Surgical Centers
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2022
11.2.2.3. Market Forecast, 2023 - 2031
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2022
11.2.2.5.1.2. Market
Forecast, 2023 - 2031
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2022
11.2.2.5.2.2. Market
Forecast, 2023 - 2031
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2022
11.2.2.5.3.2. Market
Forecast, 2023 - 2031
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2022
11.2.2.5.4.2. Market
Forecast, 2023 - 2031
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2022
11.2.2.5.5.2. Market
Forecast, 2023 - 2031
11.2.3. Cardiology
centers
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2022
11.2.3.3. Market Forecast, 2023 - 2031
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2022
11.2.3.5.1.2. Market
Forecast, 2023 - 2031
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2022
11.2.3.5.2.2. Market
Forecast, 2023 - 2031
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2022
11.2.3.5.3.2. Market
Forecast, 2023 - 2031
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2022
11.2.3.5.4.2. Market
Forecast, 2023 - 2031
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2022
11.2.3.5.5.2. Market
Forecast, 2023 - 2031
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 - 2022
11.2.4.3. Market Forecast, 2023 - 2031
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2015 - 2022
11.2.4.5.1.2. Market
Forecast, 2023 - 2031
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 - 2022
11.2.4.5.2.2. Market
Forecast, 2023 - 2031
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2015 - 2022
11.2.4.5.3.2. Market
Forecast, 2023 - 2031
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 - 2022
11.2.4.5.4.2. Market
Forecast, 2023 - 2031
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2015 - 2022
11.2.4.5.5.2. Market
Forecast, 2023 - 2031
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Users
12. North America Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
12.1. Overview
12.1.1. North
America Drug Eluting Stents(DES) Market Revenue (US$ Mn)
12.2. North
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Sirolimus
stents
12.2.2. Paclitaxel
stents
12.2.3. Everolimus stents
12.2.4. Zotarolimus
stents
12.2.5. Biolimus
stents
12.3. North
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Material
12.3.1. Cobalt
Chromium
12.3.2. Platinum
Chromium
12.3.3. Stainless
steel
12.3.4. Others
12.4. North
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Polymer Type
12.4.1. Durable
12.4.2. Biodegradable
12.4.3. Polymer
Free
12.5. North
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.1. Hospitals
12.5.2. Ambulatory
Surgical Centers
12.5.3. Cardiology
centers
12.5.4. Others
12.6. North
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.1.1.1. Sirolimus stents
12.6.1.1.2. Paclitaxel stents
12.6.1.1.3. Everolimus stents
12.6.1.1.4. Zotarolimus stents
12.6.1.1.5. Biolimus stents
12.6.1.2. U.S Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
12.6.1.2.1. Cobalt Chromium
12.6.1.2.2. Platinum Chromium
12.6.1.2.3. Stainless steel
12.6.1.2.4. Others
12.6.1.3. U.S Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
12.6.1.3.1. Durable
12.6.1.3.2. Biodegradable
12.6.1.3.3. Polymer Free
12.6.1.4. U.S Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.1.4.1. Hospitals
12.6.1.4.2. Ambulatory Surgical Centers
12.6.1.4.3. Cardiology centers
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.2.1.1. Sirolimus stents
12.6.2.1.2. Paclitaxel stents
12.6.2.1.3. Everolimus stents
12.6.2.1.4. Zotarolimus stents
12.6.2.1.5. Biolimus stents
12.6.2.2. Canada Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
12.6.2.2.1. Cobalt Chromium
12.6.2.2.2. Platinum Chromium
12.6.2.2.3. Stainless steel
12.6.2.2.4. Others
12.6.2.3. Canada Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
12.6.2.3.1. Durable
12.6.2.3.2. Biodegradable
12.6.2.3.3. Polymer Free
12.6.2.4. Canada Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.2.4.1. Hospitals
12.6.2.4.2. Ambulatory Surgical Centers
12.6.2.4.3. Cardiology centers
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
12.6.3.1.1. Sirolimus stents
12.6.3.1.2. Paclitaxel stents
12.6.3.1.3. Everolimus stents
12.6.3.1.4. Zotarolimus stents
12.6.3.1.5. Biolimus stents
12.6.3.2. Mexico Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
12.6.3.2.1. Cobalt Chromium
12.6.3.2.2. Platinum Chromium
12.6.3.2.3. Stainless steel
12.6.3.2.4. Others
12.6.3.3. Mexico Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
12.6.3.3.1. Durable
12.6.3.3.2. Biodegradable
12.6.3.3.3. Polymer Free
12.6.3.4. Mexico Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.3.4.1. Hospitals
12.6.3.4.2. Ambulatory Surgical Centers
12.6.3.4.3. Cardiology centers
12.6.3.4.4. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Type
12.6.4.1.1. Sirolimus stents
12.6.4.1.2. Paclitaxel stents
12.6.4.1.3. Everolimus stents
12.6.4.1.4. Zotarolimus stents
12.6.4.1.5. Biolimus stents
12.6.4.2. Rest of North America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Material
12.6.4.2.1. Cobalt Chromium
12.6.4.2.2. Platinum Chromium
12.6.4.2.3. Stainless steel
12.6.4.2.4. Others
12.6.4.3. Rest of North America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Polymer Type
12.6.4.3.1. Durable
12.6.4.3.2. Biodegradable
12.6.4.3.3. Polymer Free
12.6.4.4. Rest of North America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals
12.6.4.4.2. Ambulatory Surgical Centers
12.6.4.4.3. Cardiology centers
12.6.4.4.4. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By Type
12.7.3. By
Material
12.7.4. By
Polymer Type
12.7.5. By End
Users
13. Europe Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
13.1. Overview
13.1.1. Europe
Drug Eluting Stents(DES) Market Revenue (US$ Mn)
13.2. Europe
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Sirolimus
stents
13.2.2. Paclitaxel
stents
13.2.3. Everolimus stents
13.2.4. Zotarolimus
stents
13.2.5. Biolimus
stents
13.3. Europe
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Material
13.3.1. Cobalt
Chromium
13.3.2. Platinum
Chromium
13.3.3. Stainless
steel
13.3.4. Others
13.4. Europe
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Polymer Type
13.4.1. Durable
13.4.2. Biodegradable
13.4.3. Polymer
Free
13.5. Europe
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals
13.5.2. Ambulatory
Surgical Centers
13.5.3. Cardiology
centers
13.5.4. Others
13.6. Europe
Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.1.1.1. Sirolimus stents
13.6.1.1.2. Paclitaxel stents
13.6.1.1.3. Everolimus stents
13.6.1.1.4. Zotarolimus stents
13.6.1.1.5. Biolimus stents
13.6.1.2. France Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
13.6.1.2.1. Cobalt Chromium
13.6.1.2.2. Platinum Chromium
13.6.1.2.3. Stainless steel
13.6.1.2.4. Others
13.6.1.3. France Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
13.6.1.3.1. Durable
13.6.1.3.2. Biodegradable
13.6.1.3.3. Polymer Free
13.6.1.4. France Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.1.4.1. Hospitals
13.6.1.4.2. Ambulatory Surgical Centers
13.6.1.4.3. Cardiology centers
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.2.1.1. Sirolimus stents
13.6.2.1.2. Paclitaxel stents
13.6.2.1.3. Everolimus stents
13.6.2.1.4. Zotarolimus stents
13.6.2.1.5. Biolimus stents
13.6.2.2. The UK Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
13.6.2.2.1. Cobalt Chromium
13.6.2.2.2. Platinum Chromium
13.6.2.2.3. Stainless steel
13.6.2.2.4. Others
13.6.2.3. The UK Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
13.6.2.3.1. Durable
13.6.2.3.2. Biodegradable
13.6.2.3.3. Polymer Free
13.6.2.4. The UK Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.2.4.1. Hospitals
13.6.2.4.2. Ambulatory Surgical Centers
13.6.2.4.3. Cardiology centers
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.3.1.1. Sirolimus stents
13.6.3.1.2. Paclitaxel stents
13.6.3.1.3. Everolimus stents
13.6.3.1.4. Zotarolimus stents
13.6.3.1.5. Biolimus stents
13.6.3.2. Spain Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
13.6.3.2.1. Cobalt Chromium
13.6.3.2.2. Platinum Chromium
13.6.3.2.3. Stainless steel
13.6.3.2.4. Others
13.6.3.3. Spain Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
13.6.3.3.1. Durable
13.6.3.3.2. Biodegradable
13.6.3.3.3. Polymer Free
13.6.3.4. Spain Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.3.4.1. Hospitals
13.6.3.4.2. Ambulatory Surgical Centers
13.6.3.4.3. Cardiology centers
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.4.1.1. Sirolimus stents
13.6.4.1.2. Paclitaxel stents
13.6.4.1.3. Everolimus stents
13.6.4.1.4. Zotarolimus stents
13.6.4.1.5. Biolimus stents
13.6.4.2. Germany Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
13.6.4.2.1. Cobalt Chromium
13.6.4.2.2. Platinum Chromium
13.6.4.2.3. Stainless steel
13.6.4.2.4. Others
13.6.4.3. Germany Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
13.6.4.3.1. Durable
13.6.4.3.2. Biodegradable
13.6.4.3.3. Polymer Free
13.6.4.4. Germany Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.4.4.1. Hospitals
13.6.4.4.2. Ambulatory Surgical Centers
13.6.4.4.3. Cardiology centers
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.5.1.1. Sirolimus stents
13.6.5.1.2. Paclitaxel stents
13.6.5.1.3. Everolimus stents
13.6.5.1.4. Zotarolimus stents
13.6.5.1.5. Biolimus stents
13.6.5.2. Italy Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
13.6.5.2.1. Cobalt Chromium
13.6.5.2.2. Platinum Chromium
13.6.5.2.3. Stainless steel
13.6.5.2.4. Others
13.6.5.3. Italy Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
13.6.5.3.1. Durable
13.6.5.3.2. Biodegradable
13.6.5.3.3. Polymer Free
13.6.5.4. Italy Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.5.4.1. Hospitals
13.6.5.4.2. Ambulatory Surgical Centers
13.6.5.4.3. Cardiology centers
13.6.5.4.4. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Type
13.6.6.1.1. Sirolimus stents
13.6.6.1.2. Paclitaxel stents
13.6.6.1.3. Everolimus stents
13.6.6.1.4. Zotarolimus stents
13.6.6.1.5. Biolimus stents
13.6.6.2. Nordic Countries Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Material
13.6.6.2.1. Cobalt Chromium
13.6.6.2.2. Platinum Chromium
13.6.6.2.3. Stainless steel
13.6.6.2.4. Others
13.6.6.3. Nordic Countries Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Polymer Type
13.6.6.3.1. Durable
13.6.6.3.2. Biodegradable
13.6.6.3.3. Polymer Free
13.6.6.4. Nordic Countries Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals
13.6.6.4.2. Ambulatory Surgical Centers
13.6.6.4.3. Cardiology centers
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Type
13.6.7.1.1. Sirolimus stents
13.6.7.1.2. Paclitaxel stents
13.6.7.1.3. Everolimus stents
13.6.7.1.4. Zotarolimus stents
13.6.7.1.5. Biolimus stents
13.6.7.2. Benelux Union Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Material
13.6.7.2.1. Cobalt Chromium
13.6.7.2.2. Platinum Chromium
13.6.7.2.3. Stainless steel
13.6.7.2.4. Others
13.6.7.3. Benelux Union Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Polymer Type
13.6.7.3.1. Durable
13.6.7.3.2. Biodegradable
13.6.7.3.3. Polymer Free
13.6.7.4. Benelux Union Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By End Users
13.6.7.4.1. Hospitals
13.6.7.4.2. Ambulatory Surgical Centers
13.6.7.4.3. Cardiology centers
13.6.7.4.4. Others
13.6.7.5. Benelux Union Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Type
13.6.8.1.1. Sirolimus stents
13.6.8.1.2. Paclitaxel stents
13.6.8.1.3. Everolimus stents
13.6.8.1.4. Zotarolimus stents
13.6.8.1.5. Biolimus stents
13.6.8.2. Rest of Europe Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Material
13.6.8.2.1. Cobalt Chromium
13.6.8.2.2. Platinum Chromium
13.6.8.2.3. Stainless steel
13.6.8.2.4. Others
13.6.8.3. Rest of Europe Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Polymer Type
13.6.8.3.1. Durable
13.6.8.3.2. Biodegradable
13.6.8.3.3. Polymer Free
13.6.8.4. Rest of Europe Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals
13.6.8.4.2. Ambulatory Surgical Centers
13.6.8.4.3. Cardiology centers
13.6.8.4.4. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By Type
13.7.3. By
Material
13.7.4. By
Polymer Type
13.7.5. By End
Users
14. Asia Pacific Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
14.1. Overview
14.1.1. Asia
Pacific Drug Eluting Stents(DES) Market Revenue (US$ Mn)
14.2. Asia
Pacific Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Sirolimus
stents
14.2.2. Paclitaxel
stents
14.2.3. Everolimus stents
14.2.4. Zotarolimus
stents
14.2.5. Biolimus
stents
14.3. Asia
Pacific Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Material
14.3.1. Cobalt
Chromium
14.3.2. Platinum
Chromium
14.3.3. Stainless
steel
14.3.4. Others
14.4. Asia
Pacific Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Polymer Type
14.4.1. Durable
14.4.2. Biodegradable
14.4.3. Polymer
Free
14.5. Asia
Pacific Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By End
Users
14.5.1. Hospitals
14.5.2. Ambulatory
Surgical Centers
14.5.3. Cardiology
centers
14.5.4. Others
14.6. Asia
Pacific Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.1.1.1. Sirolimus stents
14.6.1.1.2. Paclitaxel stents
14.6.1.1.3. Everolimus stents
14.6.1.1.4. Zotarolimus stents
14.6.1.1.5. Biolimus stents
14.6.1.2. China Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
14.6.1.2.1. Cobalt Chromium
14.6.1.2.2. Platinum Chromium
14.6.1.2.3. Stainless steel
14.6.1.2.4. Others
14.6.1.3. China Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
14.6.1.3.1. Durable
14.6.1.3.2. Biodegradable
14.6.1.3.3. Polymer Free
14.6.1.4. China Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.1.4.1. Hospitals
14.6.1.4.2. Ambulatory Surgical Centers
14.6.1.4.3. Cardiology centers
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.2.1.1. Sirolimus stents
14.6.2.1.2. Paclitaxel stents
14.6.2.1.3. Everolimus stents
14.6.2.1.4. Zotarolimus stents
14.6.2.1.5. Biolimus stents
14.6.2.2. Japan Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
14.6.2.2.1. Cobalt Chromium
14.6.2.2.2. Platinum Chromium
14.6.2.2.3. Stainless steel
14.6.2.2.4. Others
14.6.2.3. Japan Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
14.6.2.3.1. Durable
14.6.2.3.2. Biodegradable
14.6.2.3.3. Polymer Free
14.6.2.4. Japan Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.2.4.1. Hospitals
14.6.2.4.2. Ambulatory Surgical Centers
14.6.2.4.3. Cardiology centers
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.3.1.1. Sirolimus stents
14.6.3.1.2. Paclitaxel stents
14.6.3.1.3. Everolimus stents
14.6.3.1.4. Zotarolimus stents
14.6.3.1.5. Biolimus stents
14.6.3.2. India Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
14.6.3.2.1. Cobalt Chromium
14.6.3.2.2. Platinum Chromium
14.6.3.2.3. Stainless steel
14.6.3.2.4. Others
14.6.3.3. India Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
14.6.3.3.1. Durable
14.6.3.3.2. Biodegradable
14.6.3.3.3. Polymer Free
14.6.3.4. India Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.3.4.1. Hospitals
14.6.3.4.2. Ambulatory Surgical Centers
14.6.3.4.3. Cardiology centers
14.6.3.4.4. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Type
14.6.4.1.1. Sirolimus stents
14.6.4.1.2. Paclitaxel stents
14.6.4.1.3. Everolimus stents
14.6.4.1.4. Zotarolimus stents
14.6.4.1.5. Biolimus stents
14.6.4.2. New Zealand Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Material
14.6.4.2.1. Cobalt Chromium
14.6.4.2.2. Platinum Chromium
14.6.4.2.3. Stainless steel
14.6.4.2.4. Others
14.6.4.3. New Zealand Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Polymer Type
14.6.4.3.1. Durable
14.6.4.3.2. Biodegradable
14.6.4.3.3. Polymer Free
14.6.4.4. New Zealand Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.4.4.1. Hospitals
14.6.4.4.2. Ambulatory Surgical Centers
14.6.4.4.3. Cardiology centers
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.5.1.1. Sirolimus stents
14.6.5.1.2. Paclitaxel stents
14.6.5.1.3. Everolimus stents
14.6.5.1.4. Zotarolimus stents
14.6.5.1.5. Biolimus stents
14.6.5.2. Australia Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
14.6.5.2.1. Cobalt Chromium
14.6.5.2.2. Platinum Chromium
14.6.5.2.3. Stainless steel
14.6.5.2.4. Others
14.6.5.3. Australia Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
14.6.5.3.1. Durable
14.6.5.3.2. Biodegradable
14.6.5.3.3. Polymer Free
14.6.5.4. Australia Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.5.4.1. Hospitals
14.6.5.4.2. Ambulatory Surgical Centers
14.6.5.4.3. Cardiology centers
14.6.5.4.4. Others
14.6.6. South
Korea
14.6.6.1. South Korea Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Type
14.6.6.1.1. Sirolimus stents
14.6.6.1.2. Paclitaxel stents
14.6.6.1.3. Everolimus stents
14.6.6.1.4. Zotarolimus stents
14.6.6.1.5. Biolimus stents
14.6.6.2. South Korea Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Material
14.6.6.2.1. Cobalt Chromium
14.6.6.2.2. Platinum Chromium
14.6.6.2.3. Stainless steel
14.6.6.2.4. Others
14.6.6.3. South Korea Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Polymer Type
14.6.6.3.1. Durable
14.6.6.3.2. Biodegradable
14.6.6.3.3. Polymer Free
14.6.6.4. South Korea Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.6.4.1. Hospitals
14.6.6.4.2. Ambulatory Surgical Centers
14.6.6.4.3. Cardiology centers
14.6.6.4.4. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Type
14.6.7.1.1. Sirolimus stents
14.6.7.1.2. Paclitaxel stents
14.6.7.1.3. Everolimus stents
14.6.7.1.4. Zotarolimus stents
14.6.7.1.5. Biolimus stents
14.6.7.2. Southeast Asia Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Material
14.6.7.2.1. Cobalt Chromium
14.6.7.2.2. Platinum Chromium
14.6.7.2.3. Stainless steel
14.6.7.2.4. Others
14.6.7.3. Southeast Asia Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Polymer Type
14.6.7.3.1. Durable
14.6.7.3.2. Biodegradable
14.6.7.3.3. Polymer Free
14.6.7.4. Southeast Asia Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals
14.6.7.4.2. Ambulatory Surgical Centers
14.6.7.4.3. Cardiology centers
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Drug Eluting Stents(DES) Market Revenue (US$
Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.8.1.1. Sirolimus stents
14.6.8.1.2. Paclitaxel stents
14.6.8.1.3. Everolimus stents
14.6.8.1.4. Zotarolimus stents
14.6.8.1.5. Biolimus stents
14.6.8.2. Rest of Asia Pacific Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Material
14.6.8.2.1. Cobalt Chromium
14.6.8.2.2. Platinum Chromium
14.6.8.2.3. Stainless steel
14.6.8.2.4. Others
14.6.8.3. Rest of Asia Pacific Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Polymer Type
14.6.8.3.1. Durable
14.6.8.3.2. Biodegradable
14.6.8.3.3. Polymer Free
14.6.8.4. Rest of Asia Pacific Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals
14.6.8.4.2. Ambulatory Surgical Centers
14.6.8.4.3. Cardiology centers
14.6.8.4.4. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By Type
14.7.3. By
Material
14.7.4. By
Polymer Type
14.7.5. By End
Users
15. Middle East and Africa Drug Eluting Stents(DES) Market
Analysis and Forecasts, 2023 - 2031
15.1. Overview
15.1.1. Middle
East and Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn)
15.2. Middle
East and Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts,
By Type
15.2.1. Sirolimus
stents
15.2.2. Paclitaxel
stents
15.2.3. Everolimus stents
15.2.4. Zotarolimus
stents
15.2.5. Biolimus
stents
15.3. Middle
East and Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts,
By Material
15.3.1. Cobalt
Chromium
15.3.2. Platinum
Chromium
15.3.3. Stainless
steel
15.3.4. Others
15.4. Middle
East and Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts,
By Polymer Type
15.4.1. Durable
15.4.2. Biodegradable
15.4.3. Polymer
Free
15.5. Middle
East and Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts,
By End Users
15.5.1. Hospitals
15.5.2. Ambulatory
Surgical Centers
15.5.3. Cardiology
centers
15.5.4. Others
15.6. Middle
East and Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts,
By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Type
15.6.1.1.1. Sirolimus stents
15.6.1.1.2. Paclitaxel stents
15.6.1.1.3. Everolimus stents
15.6.1.1.4. Zotarolimus stents
15.6.1.1.5. Biolimus stents
15.6.1.2. Saudi Arabia Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Material
15.6.1.2.1. Cobalt Chromium
15.6.1.2.2. Platinum Chromium
15.6.1.2.3. Stainless steel
15.6.1.2.4. Others
15.6.1.3. Saudi Arabia Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Polymer Type
15.6.1.3.1. Durable
15.6.1.3.2. Biodegradable
15.6.1.3.3. Polymer Free
15.6.1.4. Saudi Arabia Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.1.4.1. Hospitals
15.6.1.4.2. Ambulatory Surgical Centers
15.6.1.4.3. Cardiology centers
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.2.1.1. Sirolimus stents
15.6.2.1.2. Paclitaxel stents
15.6.2.1.3. Everolimus stents
15.6.2.1.4. Zotarolimus stents
15.6.2.1.5. Biolimus stents
15.6.2.2. UAE Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
15.6.2.2.1. Cobalt Chromium
15.6.2.2.2. Platinum Chromium
15.6.2.2.3. Stainless steel
15.6.2.2.4. Others
15.6.2.3. UAE Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
15.6.2.3.1. Durable
15.6.2.3.2. Biodegradable
15.6.2.3.3. Polymer Free
15.6.2.4. UAE Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.2.4.1. Hospitals
15.6.2.4.2. Ambulatory Surgical Centers
15.6.2.4.3. Cardiology centers
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.3.1.1. Sirolimus stents
15.6.3.1.2. Paclitaxel stents
15.6.3.1.3. Everolimus stents
15.6.3.1.4. Zotarolimus stents
15.6.3.1.5. Biolimus stents
15.6.3.2. Egypt Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
15.6.3.2.1. Cobalt Chromium
15.6.3.2.2. Platinum Chromium
15.6.3.2.3. Stainless steel
15.6.3.2.4. Others
15.6.3.3. Egypt Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
15.6.3.3.1. Durable
15.6.3.3.2. Biodegradable
15.6.3.3.3. Polymer Free
15.6.3.4. Egypt Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.3.4.1. Hospitals
15.6.3.4.2. Ambulatory Surgical Centers
15.6.3.4.3. Cardiology centers
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.4.1.1. Sirolimus stents
15.6.4.1.2. Paclitaxel stents
15.6.4.1.3. Everolimus stents
15.6.4.1.4. Zotarolimus stents
15.6.4.1.5. Biolimus stents
15.6.4.2. Kuwait Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
15.6.4.2.1. Cobalt Chromium
15.6.4.2.2. Platinum Chromium
15.6.4.2.3. Stainless steel
15.6.4.2.4. Others
15.6.4.3. Kuwait Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
15.6.4.3.1. Durable
15.6.4.3.2. Biodegradable
15.6.4.3.3. Polymer Free
15.6.4.4. Kuwait Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.4.4.1. Hospitals
15.6.4.4.2. Ambulatory Surgical Centers
15.6.4.4.3. Cardiology centers
15.6.4.4.4. Others
15.6.5. South Africa
15.6.5.1. South Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Type
15.6.5.1.1. Sirolimus stents
15.6.5.1.2. Paclitaxel stents
15.6.5.1.3. Everolimus stents
15.6.5.1.4. Zotarolimus stents
15.6.5.1.5. Biolimus stents
15.6.5.2. South Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Material
15.6.5.2.1. Cobalt Chromium
15.6.5.2.2. Platinum Chromium
15.6.5.2.3. Stainless steel
15.6.5.2.4. Others
15.6.5.3. South Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By Polymer Type
15.6.5.3.1. Durable
15.6.5.3.2. Biodegradable
15.6.5.3.3. Polymer Free
15.6.5.4. South Africa Drug Eluting Stents(DES) Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.5.4.1. Hospitals
15.6.5.4.2. Ambulatory Surgical Centers
15.6.5.4.3. Cardiology centers
15.6.5.4.4. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Drug Eluting Stents(DES)
Market Revenue (US$ Mn) and Forecasts, By Type
15.6.6.1.1. Sirolimus stents
15.6.6.1.2. Paclitaxel stents
15.6.6.1.3. Everolimus stents
15.6.6.1.4. Zotarolimus stents
15.6.6.1.5. Biolimus stents
15.6.6.2. Rest of Middle East & Africa Drug Eluting Stents(DES)
Market Revenue (US$ Mn) and Forecasts, By Material
15.6.6.2.1. Cobalt Chromium
15.6.6.2.2. Platinum Chromium
15.6.6.2.3. Stainless steel
15.6.6.2.4. Others
15.6.6.3. Rest of Middle East & Africa Drug Eluting Stents(DES)
Market Revenue (US$ Mn) and Forecasts, By Polymer Type
15.6.6.3.1. Durable
15.6.6.3.2. Biodegradable
15.6.6.3.3. Polymer Free
15.6.6.4. Rest of Middle East & Africa Drug Eluting Stents(DES)
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals
15.6.6.4.2. Ambulatory Surgical Centers
15.6.6.4.3. Cardiology centers
15.6.6.4.4. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Type
15.7.3. By
Material
15.7.4. By
Polymer Type
15.7.5. By End
Users
16. Latin America Drug Eluting Stents(DES) Market Analysis and
Forecasts, 2023 - 2031
16.1. Overview
16.1.1. Latin
America Drug Eluting Stents(DES) Market Revenue (US$ Mn)
16.2. Latin
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Sirolimus
stents
16.2.2. Paclitaxel
stents
16.2.3. Everolimus stents
16.2.4. Zotarolimus
stents
16.2.5. Biolimus
stents
16.3. Latin
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Material
16.3.1. Cobalt
Chromium
16.3.2. Platinum
Chromium
16.3.3. Stainless
steel
16.3.4. Others
16.4. Latin
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Polymer Type
16.4.1. Durable
16.4.2. Biodegradable
16.4.3. Polymer
Free
16.5. Latin
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By End
Users
16.5.1. Hospitals
16.5.2. Ambulatory
Surgical Centers
16.5.3. Cardiology
centers
16.5.4. Others
16.6. Latin
America Drug Eluting Stents(DES) Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.1.1.1. Sirolimus stents
16.6.1.1.2. Paclitaxel stents
16.6.1.1.3. Everolimus stents
16.6.1.1.4. Zotarolimus stents
16.6.1.1.5. Biolimus stents
16.6.1.2. Brazil Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
16.6.1.2.1. Cobalt Chromium
16.6.1.2.2. Platinum Chromium
16.6.1.2.3. Stainless steel
16.6.1.2.4. Others
16.6.1.3. Brazil Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
16.6.1.3.1. Durable
16.6.1.3.2. Biodegradable
16.6.1.3.3. Polymer Free
16.6.1.4. Brazil Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.1.4.1. Hospitals
16.6.1.4.2. Ambulatory Surgical Centers
16.6.1.4.3. Cardiology centers
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Type
16.6.2.1.1. Sirolimus stents
16.6.2.1.2. Paclitaxel stents
16.6.2.1.3. Everolimus stents
16.6.2.1.4. Zotarolimus stents
16.6.2.1.5. Biolimus stents
16.6.2.2. Argentina Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Material
16.6.2.2.1. Cobalt Chromium
16.6.2.2.2. Platinum Chromium
16.6.2.2.3. Stainless steel
16.6.2.2.4. Others
16.6.2.3. Argentina Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By Polymer Type
16.6.2.3.1. Durable
16.6.2.3.2. Biodegradable
16.6.2.3.3. Polymer Free
16.6.2.4. Argentina Drug Eluting Stents(DES) Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.2.4.1. Hospitals
16.6.2.4.2. Ambulatory Surgical Centers
16.6.2.4.3. Cardiology centers
16.6.2.4.4. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Type
16.6.3.1.1. Sirolimus stents
16.6.3.1.2. Paclitaxel stents
16.6.3.1.3. Everolimus stents
16.6.3.1.4. Zotarolimus stents
16.6.3.1.5. Biolimus stents
16.6.3.2. Rest of Latin America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Material
16.6.3.2.1. Cobalt Chromium
16.6.3.2.2. Platinum Chromium
16.6.3.2.3. Stainless steel
16.6.3.2.4. Others
16.6.3.3. Rest of Latin America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By Polymer Type
16.6.3.3.1. Durable
16.6.3.3.2. Biodegradable
16.6.3.4. Rest of Latin America Drug Eluting Stents(DES) Market Revenue
(US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals
16.6.3.4.2.
Ambulatory Surgical Centers
16.6.3.4.3.
Cardiology centers
16.6.3.4.4.
Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By Type
16.7.3. By
Material
16.7.4. By
Polymer Type
16.7.5. By End
Users
17. Competitive Benchmarking
17.1. Brand
Benchmarking
17.2. Market
Share Analysis, 2022
17.3. Global
Presence and Growth Strategies
17.3.1. Mergers
and Acquisitions
17.3.2. Product
Launches
17.3.3. Investments
Trends
17.3.4. R&D
Initiatives
18. Player Profiles
18.1. Abbott
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Alvimedica
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. BIOTRONIK
SE & Co KG
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Boston
Scientific Corporation
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Cardionovum
GmbH
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Cook
Medical
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Lepu
Medical
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Medtronic
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. MicroPort
Medical (Group) Co.,Ltd.
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Terumo
Corporation (Essen Technology Co., Ltd)
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business Strategies
18.11. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.